Hepatitis C in Australian prisons: A national needs assessment

作者: Michael Mokhlis Mina , Lilie Herawati , Tony Butler , Andrew Lloyd

DOI: 10.1108/IJPH-08-2015-0025

关键词:

摘要: Purpose – Hepatitis C (HCV) infections are prevalent in custodial settings worldwide, yet provision of antiviral therapies is uncommon. Approximately 30,000 prisoners held Australian prisons at any one time, with more than 30 per cent testing positive for HCV antibodies. Prisoners have been identified the National Strategy as a priority population assessment and treatment. The purpose this paper to examine rates treatment, well barriers opportunities development infrastructure enhanced services. Design/methodology/approach Interviews were conducted 55 stakeholders from correctional sector each state territory Australia two stages: service directors gather quantitative data regarding treatment; other qualitative information opportunities. Findings Of 50,000 individuals put custody 2013, approximatel...

参考文章(32)
G. Fattovich, Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepato-gastroenterology. ,vol. 45, pp. 1206- 1213 ,(1998)
Michael P. Manns, Thomas von Hahn, Novel therapies for hepatitis C - one pill fits all? Nature Reviews Drug Discovery. ,vol. 12, pp. 595- 610 ,(2013) , 10.1038/NRD4050
John P Bate, Anton J Colman, Peter J Frost, David R Shaw, Hugh AJ Harley, High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. Journal of Gastroenterology and Hepatology. ,vol. 25, pp. 1276- 1280 ,(2010) , 10.1111/J.1440-1746.2010.06295.X
G. Sroczynski, E. Esteban, A. Conrads-Frank, R. Schwarzer, N. Mühlberger, D. Wright, S. Zeuzem, U. Siebert, Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. Journal of Viral Hepatitis. ,vol. 17, pp. 34- 50 ,(2010) , 10.1111/J.1365-2893.2009.01147.X
Douglas R Hunt, Sammy Saab, Viral hepatitis in incarcerated adults: a medical and public health concern. The American Journal of Gastroenterology. ,vol. 104, pp. 1024- 1031 ,(2009) , 10.1038/AJG.2008.143
Stuart C. Gordon, Paul J. Pockros, Norah A. Terrault, Robert S. Hoop, Ami Buikema, David Nerenz, Fayez M. Hamzeh, Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. ,vol. 56, pp. 1651- 1660 ,(2012) , 10.1002/HEP.25842
Lorraine Yap, Susan Carruthers, Sandra Thompson, Wendy Cheng, Jocelyn Jones, Paul Simpson, Alun Richards, Hla-Hla Thein, Paul Haber, Andrew Lloyd, Tony Butler, None, A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners PLOS ONE. ,vol. 9, pp. 1- 11 ,(2014) , 10.1371/JOURNAL.PONE.0087564
Jay H. Hoofnagle, Course and outcome of hepatitis C Hepatology. ,vol. 36, pp. S21- S29 ,(2002) , 10.1002/HEP.1840360704
Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Emerging therapies for hepatitis C. Gut and Liver. ,vol. 8, pp. 471- 479 ,(2014) , 10.5009/GNL14083
Nancy S. Reau, Donald M. Jensen, Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. ,vol. 59, pp. 1246- 1249 ,(2014) , 10.1002/HEP.27039